Orion Biotechnology Canada

Orion Biotechnology is a clinical-stage biopharmaceutical company specializing in the discovery and development of precision therapeutics targeting G Protein-Coupled Receptors (GPCRs). The company utilizes its proprietary PRO-Precision Design platform to engineer high-potency drug candidates, including peptides and small molecules, that can modulate previously undruggable GPCR targets. Its lead program, OB-002, is a first-in-class CCR5 antagonist being evaluated for its potential in treating HIV-1 and various oncology indications. Orion's pipeline also extends to neuroinflammatory diseases and other chemokine receptor-driven pathologies, aiming to provide highly specific treatments with improved safety profiles.